HIV Protease Inhibitors [MoA]
Semantic Scholar uses AI to extract papers important to this topic.
ABSTRACT Human immunodeficiency virus protease inhibitors (PIs) modestly affect the plasma pharmacokinetics of tenofovir (TFV… Expand Although many of the clinically significant drug interactions of the anti-human immunodeficiency virus (HIV) protease inhibitors… Expand ABSTRACT Parasite resistance to antimalarial drugs is a serious threat to human health, and novel agents that act on enzymes… Expand Breast cancer resistance protein (BCRP) is a recently discovered ATP-binding cassette drug transporter. Hence, the full spectrum… Expand The use of highly active antiretroviral therapy in persons with acquired immunodeficiency syndrome has reduced the prevalence of… Expand ABSTRACT Intracellular accumulation of the protease inhibitors (PIs) saquinavir (SQV), ritonavir (RTV), and indinavir (IDV) was… Expand Background—Human immunodeficiency virus protease inhibitors (HIV PIs) are associated with hyperlipidemia, hyperglycemia, and… Expand Highly active antiretroviral therapy that includes human immunodeficiency virus (HIV) aspartyl protease inhibitors (PIs) causes a… Expand
To assess the pharmacokinetic interaction between ritonavir and saquinavir.
Seldom in the history of medicine has an entire generation of patients with an incurable, progressive, and ultimately fatal… Expand